Dragged down by a higher base of COVID sales of Molnupiravir and elevated input costs, the company's net profit for the January-March quarter plunged 63.89 percent on year to Rs 318.79 crore. The decline in net profit was much steeper than the nearly 58 percent fall estimated by a poll of brokerages conducted by Moneycontrol.